Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 13,201–13,300 of 15,747
Nikitina, V. A., Laurini, G. S., Montanaro, N., & Motola, D. (2023) · Acta Paediatrica · doi:10.1111/apa.16954 · Cited by 1
“18 Our results in children have shown that the majority of GBS cases occurred after the second dose, which is in line with what was reported for adults in Abolmaali's study, but in contrast to other observations.”
BackgroundResultAccelerate vaccine development using seamless phase 2/3 trial designs
Yang, J., Li, G., & Yuan, Y. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2348612 · Cited by 1
“The recent success in developing COVID-19 vaccines underscores the importance, as well as the feasibility, of fast development and approval of safe and effective vaccines [1–3].”
Turabián, J. L. (2021) · Epidemiology International Journal · doi:10.23880/eij-16000208 · Cited by 1
The mRNA vaccine contributors: Assessing their impact through a mainstream lens
Ho, M. H., Liu, J. S., Wang, W., & Chuang, T. C. (2025) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2025.124200 · Cited by 1
Tiwari, S., Kumar, M., Wu, S., Kulkarni, R., & Shah, D. K. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01273-4 · Cited by 3
“The clinical validation of this technology came with the approved mRNA vaccines for COVID-19, in which lipid nanoparticle (LNP)–encapsulated mRNAs encoding the SARS-CoV-2 spike protein proved safe and highly effective (2, 3).”
Moyue, X., Liang, S., Ying, X., Yang, Y., & Dongang, Z. (2026) · Archives of Virology · doi:10.1007/s00705-026-06569-6 · Cited by 1
SARS-CoV-2 Infection and Antibody-Dependent Enhancement
Baştuğ, A., & Bodur, H. (2021) · Studies in computational intelligence · doi:10.1007/978-3-030-74761-9_5 · Cited by 1
Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine
MacMillen, Z., Hatzakis, K., Simpson, A. C., Shears, M. J., Watson, F. N., Erasmus, J. H., Khandhar, A. P., Wilder, B. K., Murphy, S., Reed, S., et al. (2023) · bioRxiv · doi:10.21203/rs.3.rs-3045076/v1 · Cited by 3
Lee, K. H., Do, H., Choi, J. Y., Park, Y., Kim, S., Lee, S., & Jeong, S. J. (2025) · Yonsei Medical Journal · doi:10.3349/ymj.2024.0129 · Cited by 1
Stinco, G., Errichetti, E., Figini, M., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18809 · Cited by 1
Fujieda, K., Tanaka, A., Kikuchi, R., Takai, N., Saito, S., Yasuda, Y., Sano, Y., Kato, M., Furuhashi, K., & Maruyama, S. (2024) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.14114 · Cited by 1
“The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine elicits a high antibody acquisition rate in healthy individuals and has proven effective in preventing infection, severe disease, and reducing the risk of death [2 – 6].”
BackgroundBNT162b2-Elicited Neutralization of Delta Plus, Lambda, and Other VariantsPreprint
Liu, J., Liu, Y., Xia, H., Zou, J., Weaver, S. C., Swanson, K. A., Cai, H., Cutler, M. W., Cooper, D., Muik, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.13.460163 · Cited by 1
Self-citationValue-based pricing of a COVID-19 vaccine
(2021) · doi:10.1101/2021.03.06.21253035 · Cited by 1
The potential association between herpes zoster and COVID-19 vaccination
Pala, E., Bayraktar, M., & Calp, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25738 · Cited by 1
“The incidence of side-effects with mRNA vaccines is generally low [14].”
BackgroundEngaging diversity in research: does your drug work in overlooked populations?
Brown, K. E., & Woodahl, E. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817134-9.00020-9 · Cited by 1
Fernández-Murga, M. L., Serrano-García, L., D’Auria, G., Hernández, M. P., Martinez-Priego, L., Ferrús-Abad, L., de Marco, G., Domínguez-Márquez, M. V., & Llombart‐Cussac, A. (2025) · Pathogens · doi:10.3390/pathogens14090947 · Cited by 1
Taphonomical Security: DNA Information with a Foreseeable Lifespan
Orche, F.-E. E., Hollenstein, M., Houdaigoui, S., Naccache, D., Pchelina, D., Rønne, P. B., Ryan, P. Y. A., Weibel, J., & Weil, R. (2023) · Lecture notes in networks and systems · doi:10.1007/978-3-031-28073-3_46 · Cited by 1
Hiperplasia gengival durante uso de ciclosporina
Soley, G. G. O., Prado, A. I., Pereira, G. F., et al. (2020) · Arquivos de Asmas Alergia e Imunologia · doi:10.5935/2526-5393.20200058 · Cited by 1
Putri, N. D., Zhafira, A. S., Wicaksana, P., Sinto, R., Hanafi, G., Wiyono, L., Prayitno, A., Karyanti, M. R., Naibaho, M. L., Febrina, F., et al. (2024) · Vaccines · doi:10.3390/vaccines12040344 · Cited by 2
“These symptoms might be related to COVID-19 infection, although additional tests are preferable to determine the exact cause [28].”
BackgroundDevelopment of mRNA Cancer Vaccines: Delivery Strategies and Immunogenicity Optimization
Ali, A. (2025) · Current Medical Science · doi:10.1007/s11596-025-00127-y · Cited by 5
“The rapid development of two COVID-19 mRNA vaccines highlights the crucial role of mRNA technology in vaccine development and deployment [5, 9, 10, 60].”
Impact of Covid 19 Vaccination on Outcome of BP among Hospitalized Covid 19 Patients
Mateescu, D.-M., Florescu, E., István, V., Tudoran, C., Alexandra, E., Gavrilescu, D.-M., Ovidiu, R., Ilie, A. C., & Cristian, O. (2023) · Reports on Global Health Research · doi:10.29011/2690-9480.100170
“Some of these symptoms can be associated with changes in BP [26].”
BackgroundChavarría-Castro, D. Y., Reyes-Varón, E., Salgado-Cordero, A. M., Irisson-Mora, I., Morales-Bartolo, L. E., & Álvarez-Montero, F. (2023) · Revista de Salud Pública · doi:10.15446/rsap.v25n2.105359 · Cited by 1
Hoy, A., Zheng, Y. Y., Sheng, J., & Royzen, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.09.495561 · Cited by 1
Ryan, F., Norton, T. S., McCafferty, C., Blake, S., Stevens, N. E., James, J., Eden, G., Yee, T. C., Benson, S. C., Masavuli, M., et al. (2022) · medRxiv · doi:10.1101/2022.09.22.22280180
“…ChAdOx1-S (Oxford-AstraZeneca), and mRNA-1273 (Moderna) vaccines are highly effective at preventing severe COVID-19 (Falsey et al., 2021, Polack et al., 2020, Baden et al., 2021), though protection against infection wanes within 4-6 months after the second dose and two doses provide…”
BackgroundCarro, B. (2021) · All Life · doi:10.1080/26895293.2021.1977186 · Cited by 3
Scaria, P. V., Rowe, C. G., Košík, I., Hu, Z., Renn, J. P., Alani, N., Kemanli, P., Orr-Gonzalez, S., Lambert, L., Adeyemi, K., et al. (2025) · Vaccines · doi:10.3390/vaccines13060648 · Cited by 2
“The two-dose primary series of mRNA vaccines based on the WA1 Spike antigen approved for human use against SARS-CoV-2 was highly effective against severe disease [1,2].”
Disease Severity in Vaccinated Adults Hospitalized with Breakthrough COVID-19
Finn, A., Selvaraj, V., Jindal, A., Tanzer, J. R., Lal, A., & Dapaah-Afriyie, K. (2022) · Hospital Topics · doi:10.1080/00185868.2022.2118093 · Cited by 1
Yoon, H.-C. (2023) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2023.06.002 · Cited by 1
Grimes, D. R. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126657 · Cited by 1
Pugliese, M. E., Battaglia, R., Cerasa, A., Raso, M. G., Coschignano, F., Pagliuso, A., Bruschetta, R., Pugliese, G., Scola, P., & Tonin, P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245830 · Cited by 1
“Currently, vaccines authorized in the European Union (EU) to prevent COVID-19 are distinct in genetic (Pfizer–Biontech and Moderna) [5,6] or viral vector (Janssen and Vaxzevria).”
BackgroundAditi, K., Kumari, N., Singh, P., Kumari, A., Deen, S. Y., & Kumar, R. (2023) · Microsphere · doi:10.59118/vqar2242 · Cited by 1
Epitope order Matters in multi-epitope-based peptide (MEBP) vaccine design: An in silico studyPreprint
Salaikumaran, M. R., Kasamuthu, P. S., & Burra, P. V. L. S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.29.450372 · Cited by 1
“The major disadvantage of Pfizer/BioNtech Comirnaty vaccine is its stringent cold chain requirement though it has shown very good titers[51].”
BackgroundDrivers and Predictors of COVID-19 Vaccine Hesitancy in Virginia
Pilehvari, A., Ton, J., Mohan, M. R., Marathe, A., & Vullikanti, A. K. S. (2022) · Springer proceedings in complexity · doi:10.1007/978-3-030-96188-6_8 · Cited by 2
Fortin-Bédard, N., Bouchard, D., Ladry, N.-J., Lettre, J., Boucher, N., Beaulieu‐Bonneau, S., Lecours, A., Perreault, K., LeBlanc, A., Routhier, F., et al. (2024) · Work · doi:10.3233/wor-230404 · Cited by 3
Mueller, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-18903-6_1 · Cited by 1
Zhang, W., Zou, M., Zhou, Y., Tang, Q., Zhu, Y., & Xu, Y. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1624508 · Cited by 1
Guillain-Barré Syndrome After a SARS-CoV-2 Vaccine
de Oliveira, A. M., Ramos, P. V., Durão-Carvalho, G., et al. (2024) · Cureus · doi:10.7759/cureus.57705 · Cited by 1
“Acute neuroinflammatory complications have also been described, including rare cases of GBS [6,7].”
BackgroundNew-onset refractory status epilepticus after first dose of tozinameran
Tan, Y., Sim, C. Y., Narasimhalu, K., et al. (2022) · Neurology Asia · doi:10.54029/2022wuv · Cited by 1
Harnessing mRNA vaccines for viral diseases: bottleneck and breakthrough
Mishra, V. K., Ranjan, A., & Mishra, Y. (2025) · Exploration of Immunology · doi:10.37349/ei.2025.1003212 · Cited by 1
Efficacy of COVID-19 vaccines among healthcare workers in the Kingdom of Saudi Arabia
Shahrani, Z. M. A., Alnshbah, Y. I., Fallatah, S. A., Humayun, T., Albeshi, G. M., Alanazi, N., Aldalbehi, F. Z., Barnawi, E. A., Almatrafi, N. M. A., Almutairi, D. H., et al. (2025) · Journal of Clinical Virology Plus · doi:10.1016/j.jcvp.2025.100222 · Cited by 1
Zaidan, M., Bakri, A. H., & Al‐Kuwari, M. G. (2023) · Qatar journal of public health. · doi:10.5339/qjph.2023.6 · Cited by 1
Noureddine, Z., Madi, L., Ullah, S., Alrawashdeh, H., & Naseralallah, L. M. A. (2023) · Qatar medical journal · doi:10.5339/qmj.2023.10 · Cited by 2
“and subsequently piloted with three patients.(10) The severity of ADRs was categorized as mild, moderate, severe, or grade 4.”
BackgroundResultEstimate Time-To-Infection (TTI) Vaccination Effect When TTI for Unvaccinated Group is Unknown
Chen, D.-G., Chung, Y., & Beyene, K. (2024) · Statistics in Biosciences · doi:10.1007/s12561-024-09417-w · Cited by 1
Lim, R. J., Qiu, X., Leong, R. N. F., Gutierrez, J. L., Halima, A., Mostafa, M. H., Ghoneim, Y., Abdrabo, M., Rashad, M., Hannawi, S., et al. (2024) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2024.13.4.315 · Cited by 1
Vaccines for the Prevention of COVID-19 in Older Adults
Olagunju, O. J., Oyebanji, O. A., Mylonakis, E. E., & Canaday, D. H. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.09.003 · Cited by 1
Comparison of Axillary Lymph Nodes on Breast MRI Before and After COVID-19 Booster Vaccination
Parikh, R., Feigin, K., Sevilimedu, V., Huayanay, J., Pinker, K., & Horvat, J. V. (2023) · Academic Radiology · doi:10.1016/j.acra.2023.03.012 · Cited by 2
“Ipsilateral axillary lymphadenopathy following COVID-19 vaccination, shown in patients using both physical examination and imaging modalities(16-20), poses a diagnostic concern for physicians evaluating patients for new, current, or recurring breast cancer(21, 22).”
BackgroundCriteria for judging the immune markers of COVID‐19 disease vaccines
Lin, N., Fu, H., Pu, D., Quan, Y., Li, Y., Yin, X., Wei, Y., Wang, H., Ma, X., & Wei, X. (2021) · MedComm · doi:10.1002/mco2.109
Safety and efficiency of COVID-19 vaccination during pregnancy and breastfeeding
Błaszczyk, E. (2022) · Ginekologia Polska · doi:10.5603/gp.a2021.0241 · Cited by 3
Gheith, R. E., Elsebaie, E. H., Kandeel, A., et al. (2024) · The Egyptian Rheumatologist · doi:10.1016/j.ejr.2024.01.004 · Cited by 1
Chang, S., Xu, B., Xi, H., & Shao, Y. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1455718 · Cited by 3
Yamana, T. K., Galanti, M., Pei, S., et al. (2022) · medRxiv · doi:10.1101/2022.09.23.22280281 · Cited by 1
Ali, N. M., Herati, R. S., Mehta, S. A., Leonard, J., Miles, J., Lonze, B. E., DiMaggio, C. J., Tatapudi, V., Stewart, Z. A., Alnazari, N. M., et al. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14122 · Cited by 1
“1,2 5 While the high efficacy of SARS-CoV-2 messenger RNA (mRNA) vaccines was associated with protective levels of neutralizing antibodies and T-cell response in healthy adults, 6,7 several studies have shown attenuated antibody responses in immunocompromised transplant recipients.”
BackgroundCOVID-19 vaccination and immune thrombocytopenia
Abe, R., & Miyakawa, Y. (2022) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.33.576 · Cited by 1
Arnold, T. L., Barnett, A. P., Giorlando, K. K., et al. (2023) · AIDS and Behavior · doi:10.1007/s10461-023-04067-3 · Cited by 1
“The Food and Drug Administration (FDA) has approved multiple vaccines that are at least 94% efficacious in preventing COVID-19 acquisition [ 3 , 4].”
Public Health Needs the Public Trust: A Pandemic RetrospectivePreprint
Halma, M. T. J., & Guetzkow, J. (2023) · Preprints.org · doi:10.20944/preprints202302.0111.v1 · Cited by 1
Dueker, K., Capozzola, T., Feng, Z., Lin, R. N., Hurtado, J., Bangaru, S., Yuan, M., Beutler, N., Garcia, E., He, W.-T., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117439 · Cited by 3
McConney, C., Kenney, D., Ennis, C. S., Smith-Mahoney, E. L., Ayuso, M.-J., Zhong, J., Douam, F., Sagar, M., & Snyder-Cappione, J. E. (2025) · Viruses · doi:10.3390/v17050640 · Cited by 2
Aoyama, J., Iha, H., Ishikawa, M., et al. (2023) · Journal of Neuroendovascular Therapy · doi:10.5797/jnet.cr.2023-0052 · Cited by 1
“13,14) Laboratory find - ings of CVST after mRNA vaccination were characterized by normal platelet counts and negative antiplatelet factor IV antibodies.”
BackgroundAreas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients
Dimou, A. (2022) · Vaccines · doi:10.3390/vaccines10122117 · Cited by 1
“Among them, the mRNA 1273 and the BNT162b2 use lipid nanoparticle-encapsulated nucleoside-modified RNA that encodes the spike protein [14,15].”
BackgroundSaiag, E., Shalit, R., Alcalay, Y., Hasday, I., Yakubov, S., Freund, N. T., & Hagin, D. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127525 · Cited by 1
AN EXPLORATORY REVIEW OF CURRENT TRENDS IN NANODENTISTRY
REDDY, H. B., Crena, J., Prakash, P. S. G., Subramanian, S., & Appukuttan, D. (2022) · Cumhuriyet Dental Journal · doi:10.7126/cumudj.974945 · Cited by 2
Raimondi, V., Storti, P., Vescovini, R., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1532947 · Cited by 1
Pokryszka, J., Wagner, A., Wiedermann, U., Tobudic, S., Herkner, H., Winkler, S., Brehovsky, S., Reinisch, W., & Novacek, G. (2022) · Vaccines · doi:10.3390/vaccines10050759 · Cited by 1
A Case of Graves’ Disease Exacerbation Triggered by BNT162b2 Vaccination
Iwamoto, H., Kimura, T., Nakao, E., et al. (2025) · Cureus · doi:10.7759/cureus.84863 · Cited by 1
“These vaccines use mRNA encoding the SARS-CoV-2 spike protein, allowing for rapid development and high efficacy [5].”
Kotwica-Strzałek, E., Jędrych, E., Rymarz, A., Romejko, K., Smoszna, J., Korsak, J., Marczak, I., Gielerak, G. G., & Niemczyk, S. (2024) · Pediatria i Medycyna Rodzinna · doi:10.15557/pimr.2024.0026 · Cited by 1
Barc, E. D. (2022) · Journal of Biomedical and Allied Research · doi:10.37191/mapsci-2582-4937-4(1)-023
Coates, M. M., Rowe, S. L., Sullivan, S. G., Muñoz, F. M., Arah, O. A., & Regan, A. K. (2026) · Drug Safety · doi:10.1007/s40264-025-01641-7 · Cited by 1
“Randomized controlled trials (RCTs) have demonstrated the safety and efficacy of vaccines and boosters against corona-virus disease 2019 (COVID-19) [1–5].”
Baermann, B., Jäger, P. S., & Kobbe, G. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04935-3 · Cited by 1
Deamidation drives molecular aging of the SARS-CoV-2 spike receptor-binding motif
(2021) · doi:10.1101/2021.05.20.445042 · Cited by 1
“Beyond S crucial role in restricting viral host infectivity, the protein is the target of potent neutralizing antibodies (11–13) with therapeutic use and the main antigenic component of vaccines (14, 15).”
BackgroundOtsuka, S., Hiraoka, K., Suzuoki, M., Ujiie, H., Kato, T., Yokota, I., Yonezawa, K., Oguma, K., Iwashiro, N., Kato, M., et al. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.12.015 · Cited by 1
Zhang, C., Zhang, Y., Liu, R.-B., Ma, Y.-T., Zhao, L.-K., Yin, F.-Q., Tu, J., & Yao, Y. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2478319 · Cited by 1
From edits to Circuits: Nucleic acid therapeutics for Correcting human disease
Guinn, M. T., Sinenko, I., Ghanta, R. K., & Veiseh, O. (2026) · Materials Today · doi:10.1016/j.mattod.2026.103351 · Cited by 1
Prolonged angioedema after Pfizer-BioNTech COVID-19 vaccine
Fauzi, S. M. M. (2023) · BMJ Case Reports · doi:10.1136/bcr-2022-252979 · Cited by 1
Joffe, A. R., Kazemi, P., Eappen, R., & Milburn, C. (2023) · Preprints.org · doi:10.20944/preprints202310.1271.v1 · Cited by 1
Some principles for using epidemiologic study results to parameterize transmission modelsPreprint
Joshi, K., Kahn, R. J., Boyer, C., & Lipsitch, M. (2023) · medRxiv · doi:10.1101/2023.10.03.23296455 · Cited by 1
COVID-19 vaccination and menstrual disturbances: A prospective study from Pakistan
Parveen, N. (2024) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.40.7.8709 · Cited by 1
Can integrated post-exposure vaccination against SARS-COV2 mitigate severe disease?
Muller, C. P. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100118 · Cited by 1
“In the Pfizer-BioNTech phase III study the primary endpoint was defined according to FDA criteria as the presence of at least one typical COVID-19 symptom concomitant with a positive PCR test [2].”
InfluentialMaeda, M., Murata, F., & Fukuda, H. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.082 · Cited by 1
Sun, L., Huang, M., Feng, S., Zhang, W., Quan, Y., Chen, R., Yang, Y., Xu, H., Li, W., Pan, Q., et al. (2025) · Journal of Virology · doi:10.1128/jvi.01209-25 · Cited by 2
“However, when adjusted for body weight, these murine doses are substantially higher than the 30–100 µg doses used in human clinical trials for prophylactic mRNA vaccines (20, 30–32, 42, 43).”
Zhang, M., Pan, X., Li, J., & Wang, H. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.112358 · Cited by 3
Liu, C. X., Zhang, K., Ge, R., Wang, W., Liu, X., Li, X., Hao, P., & Li, H. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202502567 · Cited by 5
Feder, K. A., Patel, A., Vepachedu, V. R., et al. (2021) · medRxiv · doi:10.1101/2021.07.29.21261006 · Cited by 4
Is Low-Dose Lung Radiotherapy for Severe COVID-19 Pneumonia a Therapeutic Alternative?
Safini, F., Amaoui, B., Oqbani, K., Abbaoui, S., & Semghouli, S. (2024) · Cureus · doi:10.7759/cureus.65033 · Cited by 1
Ikrar, T., Muchsin, W., & Sophian, A. (2026) · Antiviral Research · doi:10.1016/j.antiviral.2026.106487 · Cited by 1
Nakata, T., Chiba, A., Fujii, D., et al. (2025) · Japanese Economic Review · doi:10.1007/s42973-025-00224-6 · Cited by 1
Jiang, W., Wu, J., He, J., Xia, A., Wu, W., Gao, Y., Zhang, Q., Peng, X., Jiang, Q., Xue, S., et al. (2024) · Vaccines · doi:10.3390/vaccines12111204 · Cited by 1
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.